Wenfeng Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenfeng Zeng has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Wei Liang
Protein and Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China
17 shared publications Fayun Zhang
Protein and Peptide Pharmaceutical Laboratory, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
8 shared publications- Luoyang Wang
Department of Immunology, School of Basic Medical College Qingdao University Qingdao Shandong P. R. China
6 shared publications Xiuli Wei
Protein and Peptide Pharmaceutical Laboratory Institute of Biophysics Chinese Academy of Sciences Beijing 100101 China
6 shared publications- Chunling Zhang
Chinese Academy of Sciences
5 shared publications Zihao Wang
National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China
5 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Wiley in International Endodontic Journal
Sleep Deprivation Exacerbates Pulpal Inflammation and Impairs Repair Through Dysregulated Neutrophil Activity in Rats
Aim: To investigate the effects of sleep deprivation on pulpal inflammation and repair and determine the contribution of neutrophil activity to these changes in rat models. Methodology: Sleep deprivation was induced in rats using a modified multiple platform method. Pulp responses were evaluated using three experimental settings. Under baseline conditions, rats underwent acute sleep deprivation for four consecutive days. In the inflammatory model, pulpitis was induced by lipopolysaccharide (LPS) and assessed 1–4 days after induction. In the reparative model, direct pulp capping (DPC) was performed and pulpal healing was assessed at 14 and 28 days during sleep deprivation. Histological, vascular and inflammatory changes were evaluated by haematoxylin and eosin staining, Masson's trichrome staining, immunohistochemistry and immunofluorescence. Transcriptomic alterations in pulp tissue were analysed by mRNA sequencing. Neutrophil abundance and activation were assessed in peripheral blood and dental pulp by complete blood counts, flow cytometry and myeloperoxidase staining. To investigate the functional contribution of neutrophils and neutrophil elastase (NE), sleep‐deprived rats were treated with the neutrophil‐depleting antibody or the NE inhibitor Sivelestat. Results: Sleep deprivation disrupted pulpal homeostasis, inducing vascular alterations and inflammatory cell infiltration. Following DPC, sleep‐deprived rats exhibited impaired repair, including incomplete hard tissue bridge formation and reduced osteopontin expression at Day 14, followed by pulpal necrosis and apical periodontitis at Day 28. In the LPS‐induced pulpitis model, sleep deprivation accelerated inflammatory progression and increased pulpal necrosis and leukocyte accumulation. Transcriptomic analysis revealed enrichment of immune‐ and neutrophil‐associated pathways. Sleep deprivation increased neutrophil abundance, accumulation and activation in dental pulp, accompanied by elevated NE expression and enhanced neutrophil extracellular trap–like signals. Neutrophil depletion attenuated pulpal inflammation and tissue injury, while pharmacological inhibition of NE reduced inflammatory responses and pulpal tissue damage. Conclusions: Sleep deprivation exacerbates pulpal inflammation and impairs repair, at least in part through enhanced neutrophil activity and NE‐mediated tissue injury. These findings reveal a mechanistic link between sleep disturbance and dysregulated pulpal inflammation and suggest neutrophil/NE‐associated pathways as potential targets for further investigation.
- 17 November 2026
- Published by Wiley in International Endodontic Journal
Open AccessSleep Deprivation Exacerbates Pulpal Inflammation and Impairs Repair Through Dysregulated Neutrophil Activity in Rats
Aim: To investigate the effects of sleep deprivation on pulpal inflammation and repair and determine the contribution of neutrophil activity to these changes in rat models. Methodology: Sleep deprivation was induced in rats using a modified multiple platform method. Pulp responses were evaluated using three experimental settings. Under baseline conditions, rats underwent acute sleep deprivation for four consecutive days. In the inflammatory model, pulpitis was induced by lipopolysaccharide (LPS) and assessed 1–4 days after induction. In the reparative model, direct pulp capping (DPC) was performed and pulpal healing was assessed at 14 and 28 days during sleep deprivation. Histological, vascular and inflammatory changes were evaluated by haematoxylin and eosin staining, Masson's trichrome staining, immunohistochemistry and immunofluorescence. Transcriptomic alterations in pulp tissue were analysed by mRNA sequencing. Neutrophil abundance and activation were assessed in peripheral blood and dental pulp by complete blood counts, flow cytometry and myeloperoxidase staining. To investigate the functional contribution of neutrophils and neutrophil elastase (NE), sleep‐deprived rats were treated with the neutrophil‐depleting antibody or the NE inhibitor Sivelestat. Results: Sleep deprivation disrupted pulpal homeostasis, inducing vascular alterations and inflammatory cell infiltration. Following DPC, sleep‐deprived rats exhibited impaired repair, including incomplete hard tissue bridge formation and reduced osteopontin expression at Day 14, followed by pulpal necrosis and apical periodontitis at Day 28. In the LPS‐induced pulpitis model, sleep deprivation accelerated inflammatory progression and increased pulpal necrosis and leukocyte accumulation. Transcriptomic analysis revealed enrichment of immune‐ and neutrophil‐associated pathways. Sleep deprivation increased neutrophil abundance, accumulation and activation in dental pulp, accompanied by elevated NE expression and enhanced neutrophil extracellular trap–like signals. Neutrophil depletion attenuated pulpal inflammation and tissue injury, while pharmacological inhibition of NE reduced inflammatory responses and pulpal tissue damage. Conclusions: Sleep deprivation exacerbates pulpal inflammation and impairs repair, at least in part through enhanced neutrophil activity and NE‐mediated tissue injury. These findings reveal a mechanistic link between sleep disturbance and dysregulated pulpal inflammation and suggest neutrophil/NE‐associated pathways as potential targets for further investigation.
- 23 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7904-7919
Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Although an immune checkpoint blockade can reduce metastasis, its effectiveness is hindered by the immunosuppressive microenvironment in TNBC. EZH2 is overexpressed in TNBC, and patients with high EZH2 expression are associated with poor prognoses. The study developed EIP103 as a first-in-class peptide degrader that targets EZH2 through multivalent, high-affinity interactions and induces conformational destabilization, representing a mechanism distinct from that of the small molecule inhibitor EPZ-6438. The results demonstrated that EIP103 induces immunogenic cell death through lipid peroxidation, resulting in enhanced immune cell infiltration. Additionally, molecular dynamics (MD) simulations and biochemical assays revealed that the peptide EIP103 binds to the SET domain of EZH2, altering its structure and triggering proteasomal degradation via Praja Ring Finger Ubiquitin Ligase 2 (PJA2)-mediated ubiquitination. Harboring both enzymatic inhibition and post-translational regulation properties, EIP103 exerts durable efficacy and activates antitumor immunity, making it a promising therapeutic candidate for TNBC.
- 23 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 7904-7919
Multivalent Peptide-Guided EZH2 Degradation Sensitizes Immune Checkpoint Therapy in TNBC
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Although an immune checkpoint blockade can reduce metastasis, its effectiveness is hindered by the immunosuppressive microenvironment in TNBC. EZH2 is overexpressed in TNBC, and patients with high EZH2 expression are associated with poor prognoses. The study developed EIP103 as a first-in-class peptide degrader that targets EZH2 through multivalent, high-affinity interactions and induces conformational destabilization, representing a mechanism distinct from that of the small molecule inhibitor EPZ-6438. The results demonstrated that EIP103 induces immunogenic cell death through lipid peroxidation, resulting in enhanced immune cell infiltration. Additionally, molecular dynamics (MD) simulations and biochemical assays revealed that the peptide EIP103 binds to the SET domain of EZH2, altering its structure and triggering proteasomal degradation via Praja Ring Finger Ubiquitin Ligase 2 (PJA2)-mediated ubiquitination. Harboring both enzymatic inhibition and post-translational regulation properties, EIP103 exerts durable efficacy and activates antitumor immunity, making it a promising therapeutic candidate for TNBC.
- Open Access
- 10 April 2025
- Published by Elsevier in Biomaterials
- Vol. 321, 123333
P-Pev: micelle-like complexes transformed from tumor extracellular vesicles by PEG-PE for personalized therapeutic tumor vaccine
- 10 April 2025
- Published by Elsevier in Biomaterials
- Vol. 321, 123333
Open AccessP-Pev: micelle-like complexes transformed from tumor extracellular vesicles by PEG-PE for personalized therapeutic tumor vaccine
- Open Access
- 24 June 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (4) , 300-306
PKM2, the “K+ sink” in the tumor interstitial fluid
Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang; PKM2, the “K+ sink” in the tumor interstitial
- 24 June 2024
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 16 (4) , 300-306
Open AccessPKM2, the “K+ sink” in the tumor interstitial fluid
Wenjing Na, Wenfeng Zeng, Kai Song, Youwang Wang, Luoyang Wang, Ziran Zhao, Lingtao Jin, Ping Zhu, Wei Liang; PKM2, the “K+ sink” in the tumor interstitial
- Open Access
- 1 November 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (3)
Stable IL‐2 Nano‐Assembly for Improved Anti‐Tumor Effect
Interleukin 2 (IL‐2) is the first approved immune therapeutic drug to treat cancer, however various off‐target effects and intolerable dose‐related toxicities induced by high‐dose intravenous infusion regimens result in a large proportion of patients require dose reduction, preventing the widespread adoption of this treatment. To address these issues, a novel IL‐2 nano‐assembly formulation (nano‐IL‐2) is developed using distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐n‐[methoxy (polyethylene glycol)‐2000] (PEG2000‐DSPE), which is durably stable due to the high binding affinity (10–8 m level) of two components and hardly induces vascular leak or inflamed injury at the injection site. Besides, nano‐IL‐2 exerts excellent solubility, lymph‐targeting property, prolonged and stable serum IL‐2 concentration ranges, and much lower toxicities compared to commercial formulation. Monotherapy of nano‐IL‐2 shows optimal capability to control the growth of murine melanoma and colon cancer. Collectively, the present study provides a novel design strategy for lymph‐targeting IL‐2 formulation which is more suitable for subcutaneous administration with higher safety concern.
- 1 November 2023
- Published by Wiley in Advanced Therapeutics
- Vol. 7 (3)
Open AccessStable IL‐2 Nano‐Assembly for Improved Anti‐Tumor Effect
Interleukin 2 (IL‐2) is the first approved immune therapeutic drug to treat cancer, however various off‐target effects and intolerable dose‐related toxicities induced by high‐dose intravenous infusion regimens result in a large proportion of patients require dose reduction, preventing the widespread adoption of this treatment. To address these issues, a novel IL‐2 nano‐assembly formulation (nano‐IL‐2) is developed using distearoyl‐sn‐glycero‐3‐phosphoethanolamine‐n‐[methoxy (polyethylene glycol)‐2000] (PEG2000‐DSPE), which is durably stable due to the high binding affinity (10–8 m level) of two components and hardly induces vascular leak or inflamed injury at the injection site. Besides, nano‐IL‐2 exerts excellent solubility, lymph‐targeting property, prolonged and stable serum IL‐2 concentration ranges, and much lower toxicities compared to commercial formulation. Monotherapy of nano‐IL‐2 shows optimal capability to control the growth of murine melanoma and colon cancer. Collectively, the present study provides a novel design strategy for lymph‐targeting IL‐2 formulation which is more suitable for subcutaneous administration with higher safety concern.
- Open Access
Complexes Formed by Mixing Tumor-derived Extracellular Vesicles with Polymeric Surfactants for Personalized Therapeutic Vaccine
The personalized therapeutic vaccine is an ideal weapon to eliminate tumors. However, the core steps of manufacturing personalized cancer vaccines are identifying tumor-specific antigens (TSAs, also called neoantigens) and HLA epitope prediction, which is time-consuming and labor-intense. Tumor-derived extracellular vesicles (TEVs) are alternative sources of neoantigens. However, the immunosuppressive nature of TEVs limits their application in such immunotherapy. In this study, we present a new strategy to maintain neoantigens in TEVs and diminish the immunosuppression by deconstructing the structure of TEVs with polymeric surfactant polyethylene glycol-phosphatidylethanolamine (PEG-PE). Together with adjuvant MPLA, the newly formed micelle-like complexes compose a therapeutic vaccine (MLC-V). Results show that MLC-V is capable of eliciting neoantigen-specific T-cell responses, restoring TEV-induced immunosuppression, and preventing lung metastasis of murine melanoma. MLC-V also exhibits outstanding anti-tumor efficacy in multiple tumor models. MLC-V can be used as a personalized therapeutic vaccine in a mimetic pre-clinical MC38 model and the anti-tumor effect of MLC-V was synergistically enhanced by PD-1 mAb. Taken together, the present study demonstrates a time-saving, low-cost, and simplified strategy to produce personalized therapeutic vaccines based on MLC-V platform technology.
Open AccessComplexes Formed by Mixing Tumor-derived Extracellular Vesicles with Polymeric Surfactants for Personalized Therapeutic Vaccine
The personalized therapeutic vaccine is an ideal weapon to eliminate tumors. However, the core steps of manufacturing personalized cancer vaccines are identifying tumor-specific antigens (TSAs, also called neoantigens) and HLA epitope prediction, which is time-consuming and labor-intense. Tumor-derived extracellular vesicles (TEVs) are alternative sources of neoantigens. However, the immunosuppressive nature of TEVs limits their application in such immunotherapy. In this study, we present a new strategy to maintain neoantigens in TEVs and diminish the immunosuppression by deconstructing the structure of TEVs with polymeric surfactant polyethylene glycol-phosphatidylethanolamine (PEG-PE). Together with adjuvant MPLA, the newly formed micelle-like complexes compose a therapeutic vaccine (MLC-V). Results show that MLC-V is capable of eliciting neoantigen-specific T-cell responses, restoring TEV-induced immunosuppression, and preventing lung metastasis of murine melanoma. MLC-V also exhibits outstanding anti-tumor efficacy in multiple tumor models. MLC-V can be used as a personalized therapeutic vaccine in a mimetic pre-clinical MC38 model and the anti-tumor effect of MLC-V was synergistically enhanced by PD-1 mAb. Taken together, the present study demonstrates a time-saving, low-cost, and simplified strategy to produce personalized therapeutic vaccines based on MLC-V platform technology.
- Open Access
- 1 March 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (1) , 100361
In vitro and ex vivo evaluation of tumor-derived exosome-induced dendritic cell dysfunction in mouse
- 1 March 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (1) , 100361
Open AccessIn vitro and ex vivo evaluation of tumor-derived exosome-induced dendritic cell dysfunction in mouse
- Open Access
- 1 January 2021
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1981570
Downregulating testosterone levels enhance immunotherapy efficiency
Low response rates to certain tumor types remain a major challenge for immune checkpoint blockade therapy. In this study, we first conducted an integrated biomarker evaluation of bladder cancer patients from confirmatory cohorts (IMvigor210) and found that no significant differences exist between sexes before acceptance of anti-PD-L1 treatment, whereas male patients showed a better response. Thus, we then focused on sex-related changes post anti-PD-L1 treatment and found no obvious impact on the gut microbiota in male mice but a significant decrease in the sex hormone levels. Further, castration dramatically enhanced the antitumor efficacy against murine colon adenocarcinoma in male mice. Moreover, a narrow-spectrum antibiotic, colistin was innovatively used for deregulation of testosterone levels to enhance the immunotherapy efficiency in male mice. These findings indicate that the impact on the sex hormone levels in males may contribute to the sexual dimorphism in response and provide a promising way to enhance immunotherapy efficiency.
- 1 January 2021
- Published by Taylor & Francis in OncoImmunology
- Vol. 10 (1) , 1981570
Open AccessDownregulating testosterone levels enhance immunotherapy efficiency
Low response rates to certain tumor types remain a major challenge for immune checkpoint blockade therapy. In this study, we first conducted an integrated biomarker evaluation of bladder cancer patients from confirmatory cohorts (IMvigor210) and found that no significant differences exist between sexes before acceptance of anti-PD-L1 treatment, whereas male patients showed a better response. Thus, we then focused on sex-related changes post anti-PD-L1 treatment and found no obvious impact on the gut microbiota in male mice but a significant decrease in the sex hormone levels. Further, castration dramatically enhanced the antitumor efficacy against murine colon adenocarcinoma in male mice. Moreover, a narrow-spectrum antibiotic, colistin was innovatively used for deregulation of testosterone levels to enhance the immunotherapy efficiency in male mice. These findings indicate that the impact on the sex hormone levels in males may contribute to the sexual dimorphism in response and provide a promising way to enhance immunotherapy efficiency.
- Open Access
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (3) , 108278
PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction
- 1 October 2020
- Published by Elsevier in Cell Reports
- Vol. 33 (3) , 108278
Open AccessPPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction